Company Performance Metrics
TerThera focuses on the production and commercial supply of non-carrier-added Terbium-161 in GMP-compliant form for use in radioligand therapy. The company manufactures Terbium-161 by neutron activation of enriched Gadolinium-160 in research reactors and delivers it as an aqueous 0.05M HCl solution. Terbium-161 supplied by TerThera is intended for
radiopharmaceutical developers, hospitals, and research organizations that use radiolanthanides in targeted cancer therapies. Its product supports existing radiolabeling techniques and is used to optimize therapeutic dosing, imaging quality, and radiation safety in treatment planning. TerThera concentrates on enabling wider access to Terbium-161 for clinical and research applications in nuclear medicine and oncology.
